Holen Sie sich die Stockscreener-App
6.37
6.60%
-0.45
Handel nachbörslich:
6.37
Schlusskurs vom Vortag:
$6.82
Offen:
$6.9
24-Stunden-Volumen:
136.81K
Relative Volume:
0.92
Marktkapitalisierung:
$162.16M
Einnahmen:
-
Nettoeinkommen (Verlust:
$-22.38M
KGV:
-4.5177
EPS:
-1.41
Netto-Cashflow:
$-15.54M
1W Leistung:
-1.39%
1M Leistung:
-19.16%
6M Leistung:
-8.35%
1J Leistung:
-1.39%
1-Tages-Spanne:
$6.3401
$6.99
1-Wochen-Bereich:
$5.85
$6.99
52-Wochen-Spanne:
$4.44
$11.80
Nuvectis Pharma Inc Stock (NVCT) Company Profile
Firmenname
Nuvectis Pharma Inc
Sektor
Branche
Telefon
360-837-7232
Adresse
1 BRIDGE PLAZA, SUITE 275, FORT LEE
Vergleichen Sie NVCT mit anderen Aktien
| Aktien | Preis | Marktkapitalisierung | Umsatz | Nettogewinn | Free Cashflow | ENV |
|---|---|---|---|---|---|---|
NVCT
Nuvectis Pharma Inc
|
6.37 | 156.05M | 0 | -22.38M | -15.54M | -1.41 |
|
VRTX
Vertex Pharmaceuticals Inc
|
395.92 | 99.42B | 11.42B | 3.64B | 3.50B | 13.99 |
|
REGN
Regeneron Pharmaceuticals Inc
|
561.55 | 58.99B | 14.21B | 4.46B | 3.56B | 39.68 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
432.52 | 56.35B | 2.46B | -319.09M | -52.09M | -2.47 |
|
ARGX
Argen X Se Adr
|
646.60 | 39.02B | 3.05B | 1.28B | -614.78M | 19.58 |
|
ONC
Beone Medicines Ltd Adr
|
307.51 | 34.25B | 3.81B | -644.79M | -669.77M | -6.24 |
Nuvectis Pharma Inc Stock (NVCT) Upgrades & Downgrades
| Datum | Aktion | Analytiker | Ratingänderung |
|---|---|---|---|
| 2025-04-02 | Eingeleitet | Maxim Group | Buy |
| 2025-03-17 | Eingeleitet | Laidlaw | Buy |
| 2022-07-13 | Eingeleitet | Ladenburg Thalmann | Buy |
Nuvectis Pharma Inc Aktie (NVCT) Neueste Nachrichten
Is Nuvectis Pharma Inc. building a consolidation base2025 Dividend Review & Daily Chart Pattern Signal Reports - Newser
What indicators show strength in Nuvectis Pharma Inc.Earnings Beat & Reliable Price Breakout Signals - Newser
Evaluating Nuvectis Pharma Inc. with trendline analysisGDP Growth & Verified High Yield Trade Plans - Newser
Using R and stats models for Nuvectis Pharma Inc. forecastingPortfolio Risk Report & Entry Point Confirmation Alerts - Newser
Is Nuvectis Pharma Inc. trending in predictive chart modelsAI Entry Timing Prediction for Swing Traders - Newser
what makes nuvectis pharma inc. stock price move sharplyFree Buy Signal Based on Chart Analysis - Newser
Does Nuvectis Pharma Inc. fit your quant trading model2025 Analyst Calls & Detailed Earnings Play Strategies - Newser
Developing predictive dashboards with Nuvectis Pharma Inc. dataFree Price Action Based Buy Opportunity List - Newser
What makes Nuvectis Pharma Inc. stock price move sharplyWeekly Breakout Forecast with Entry Zones - Newser
Nuvectis initiates phase 1b program for cancer drug NXP900 - Investing.com
Nuvectis Pharma Announces the Initiation of the Phase 1b Program for NXP900 - GlobeNewswire
Nuvectis Expands Cancer Drug Trial to Target Multiple Resistant Tumors with Precision Medicine - Stock Titan
Key resistance and support levels for Nuvectis Pharma Inc.Volume Spike Detection for Early Breakouts - Newser
Is it time to cut losses on Nuvectis Pharma Inc.Fed Meeting & Daily Oversold Bounce Ideas - Newser
How to track smart money flows in Nuvectis Pharma Inc.Strategy Builder for Growth Focused Traders - Newser
Volume spikes in Nuvectis Pharma Inc. stock – what they meanFree Pattern Detection for Entry Confirmation - Newser
Nuvectis Pharma (NASDAQ:NVCT) Is In A Good Position To Deliver On Growth Plans - 富途牛牛
Nuvectis Pharma, Inc.'s (NASDAQ:NVCT) stock price dropped 12% last week; retail investors would not be happy - simplywall.st
RSI Suggests Rebound May Be Near in Nuvectis Pharma Inc.Breakout Confirmation With Entry Tracker Enabled - beatles.ru
Will Nuvectis Pharma Inc. stock recover after recent dropReal Time Trade Execution Alert Plan - Newser
How to forecast Nuvectis Pharma Inc. trends using time seriesWatchlist Generator for Smart Money Signals - Newser
Why Nuvectis Pharma Inc. stock attracts strong analyst attentionFree Expert Verified Stock Trade Ideas - Newser
Nuvectis Pharma cuts NXP800 in ovarian cancer after early failure - MSN
Nuvectis Pharma Inc. stock daily chart insightsSwing Watchlist With Tight Stop Placement - Newser
Nuvectis Pharma Inc. Stock Chart Analysis: Bullish or Bearish Pattern FormingTrend Reversal Watch with Entry Signals - Newser
Q3 EPS Estimates for Nuvectis Pharma Reduced by Roth Capital - Defense World
Will a bounce in Nuvectis Pharma Inc. offer an exitFree Consistent Profit Pattern Recognition Tools - Newser
Nuvectis Pharma’s Strategic Focus on NXP900 and Positive Outlook Amidst Promising Developments - TipRanks
Nuvectis Pharma Reports Q2 2025 Financial Results and Progress - TipRanks
Exit strategy if you’re trapped in Nuvectis Pharma Inc.Stable Profit Zone and Loss Control Analysis - Newser
Nuvectis Pharma reports Q2 EPS (30c) vs. (26c) last year - TipRanks
Nuvectis Pharma: A Biotech Gem in the Shadows of GAAP Losses - AInvest
Nuvectis Pharma, Inc. Reports Second Quarter 2025 Financial Results and Business Highlights - The Manila Times
Nuvectis Reports Clinical Trial Success: NXP900 Cancer Drug Advances as Cash Position Strengthens to $39M - Stock Titan
Nuvectis Pharma (NASDAQ:NVCT) Given New $10.00 Price Target at HC Wainwright - Defense World
HC Wainwright Lowers Nuvectis Pharma (NASDAQ:NVCT) Price Target to $10.00 - Defense World
Finanzdaten der Nuvectis Pharma Inc-Aktie (NVCT)
Umsatz
Nettogewinn
Free Cashflow
ENV
Nuvectis Pharma Inc-Aktie (NVCT) Insiderhandel
| Insiderhandel | Beziehung | Datum | Transaktion | Kosten | #Aktien | Wert ($) | #Aktien Gesamt |
|---|---|---|---|---|---|---|---|
| Mosseri Marlio Charles | 10% Owner |
Jun 18 '25 |
Buy |
8.05 |
28,043 |
225,746 |
2,976,203 |
| Mosseri Marlio Charles | 10% Owner |
Jun 17 '25 |
Buy |
8.11 |
5,399 |
43,786 |
2,948,160 |
| Mosseri Marlio Charles | 10% Owner |
May 12 '25 |
Buy |
8.11 |
21,167 |
171,664 |
2,942,761 |
| Mosseri Marlio Charles | 10% Owner |
May 06 '25 |
Buy |
8.59 |
12,444 |
106,955 |
2,896,565 |
| Mosseri Marlio Charles | 10% Owner |
May 07 '25 |
Buy |
8.59 |
12,317 |
105,770 |
2,908,882 |
| Mosseri Marlio Charles | 10% Owner |
May 08 '25 |
Buy |
8.65 |
2,650 |
22,922 |
2,911,532 |
| Mosseri Marlio Charles | 10% Owner |
Feb 07 '25 |
Buy |
5.00 |
240,000 |
1,200,000 |
2,884,121 |
| BENTSUR RON | Chairman & CEO |
Dec 24 '24 |
Buy |
4.65 |
4,500 |
20,925 |
3,270,924 |
| Mosseri Marlio Charles | 10% Owner |
Dec 13 '24 |
Buy |
4.70 |
17,000 |
79,900 |
2,612,000 |
| Poradosu Enrique | Chief Science & Business Off |
Nov 19 '24 |
Buy |
4.99 |
2,000 |
9,980 |
1,506,319 |
1.67%
In Yahoo öffnen
|
In Google öffnen
|
In Finviz öffnen
|
In MarketWatch öffnen
|
Öffnen Sie in EDGAR
|
Offen in Reuters
Kapitalisierung:
|
Volumen (24h):